Home / Deep Research / Carnitine-acylcarnitine Translocase Deficiency

Carnitine-acylcarnitine Translocase Deficiency

Disease Pathophysiology Research Template

2026-02-23
Falcon MONDO:0008918 Model: Edison Scientific Literature 40 citations

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Carnitine-acylcarnitine Translocase Deficiency
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Carnitine-acylcarnitine Translocase Deficiency. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Title: Pathophysiology Research Report — Carnitine‑acylcarnitine Translocase Deficiency (CACTD; SLC25A20 deficiency)

Target disease - Disease: Carnitine‑acylcarnitine translocase deficiency (CACTD) - MONDO ID: MONDO:0008918 (as indexed in Open Targets disease–target association output for “carnitine‑acylcarnitine translocase deficiency”) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2) - Category: Genetic (autosomal recessive) long‑chain fatty‑acid oxidation disorder (LC‑FAOD) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8)

1) Key concepts and definitions (current understanding)

1.1 Definition CACTD is caused by biallelic pathogenic variants in SLC25A20, encoding the mitochondrial inner membrane carnitine‑acylcarnitine translocase (CACT), a solute carrier family 25 transporter required for the carnitine shuttle (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, elgharbawy2018inbornerrorsof pages 4-6).

A concise mechanistic definition from a 2024 autopsy case report: CACT is “responsible for the unidirectional transport of acylcarnitine across the inner mitochondrial membrane” and is “a crucial role in the oxidation of fatty acids” (Thunga et al., 2024-04; https://doi.org/10.4322/acr.2024.483) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5).

1.2 Carnitine shuttle context (molecular concept) Physiologic long‑chain fatty acid (LCFA) β‑oxidation requires: (i) CPT1 (outer mitochondrial membrane) to form long‑chain acylcarnitines, (ii) CACT/SLC25A20 (inner membrane) to exchange acylcarnitine for carnitine across the inner membrane, and (iii) CPT2 (matrix side) to regenerate long‑chain acyl‑CoA for β‑oxidation (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, elgharbawy2018inbornerrorsof pages 4-6). A schematic pathway depiction of CACT’s role in LCFA entry into the mitochondrial matrix is shown in Thunga et al. 2024 (Figure 4) (thunga2024carnitineacylcarnitinetranslocasedeficiency media a9332e20).

1.3 Core biochemical/clinical pattern Because newborns and fasting/stress states rely heavily on LCFA oxidation, CACTD classically presents with acute energy failure: hypoketotic hypoglycemia and hyperammonemia, with frequent cardiomyopathy/arrhythmia, hepatic dysfunction/hepatomegaly, skeletal myopathy/rhabdomyolysis, and encephalopathy; sudden unexpected death has been reported (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, elgharbawy2018inbornerrorsof pages 4-6, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2).

2) Core pathophysiology (molecular and cellular mechanisms)

2.1 Primary pathophysiological mechanisms Mechanistic chain (canonical): 1) SLC25A20 loss‑of‑function → impaired transport of long‑chain acylcarnitines into the mitochondrial matrix (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5, elgharbawy2018inbornerrorsof pages 4-6). 2) Blocked LCFA β‑oxidation → inadequate ATP generation during fasting/birth/illness and impaired ketogenesis (hypoketosis), shifting reliance to glucose until glycogen is depleted (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8). 3) Accumulation of long‑chain acylcarnitines/acyl‑CoA derivatives and secondary free carnitine depletion → biochemical toxicity and organ dysfunction, particularly in high‑energy tissues (heart, skeletal muscle, liver, kidney) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2).

2.2 Dysregulated pathways - Mitochondrial long‑chain fatty‑acid β‑oxidation and associated ketone body production (energy metabolism pathway failure) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, elgharbawy2018inbornerrorsof pages 4-6). - Mitochondrial carnitine cycle / carnitine shuttle transport across the inner mitochondrial membrane (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5, thunga2024carnitineacylcarnitinetranslocasedeficiency media a9332e20). - Secondary metabolic responses: hypoketotic hypoglycemia, hyperammonemia, dicarboxylic aciduria (reflecting ω‑oxidation and incomplete oxidation) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, kheirandish2024theroleof pages 8-8).

2.3 Cellular processes affected - Mitochondrial substrate transport and matrix substrate availability (acylcarnitine ↔ carnitine exchange) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5, pasquadibisceglie2023insilicoanalysis pages 1-2). - Oxidative energy production under catabolic stress (fasting/illness) leading to cellular energy deficit (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2). - Lipid handling and storage: microvesicular steatosis in multiple cell types (hepatocytes, myocytes, renal proximal tubule epithelium) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency media 218ed3a6).

3) Key molecular players

3.1 Genes/proteins (HGNC) - SLC25A20 (solute carrier family 25 member 20; CACT/CAC): causal gene; mitochondrial inner membrane transporter (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5). - CPT1/CPT2: upstream/downstream carnitine shuttle enzymes; CACTD biochemically overlaps with CPT2 deficiency on acylcarnitine profiling, requiring genetic/enzymatic confirmation for discrimination (elgharbawy2018inbornerrorsof pages 4-6).

3.2 2023 structural/mechanistic insights on SLC25A20 A 2023 in silico study modeled SLC25A20 conformational cycling consistent with an alternating‑access mechanism and reported “a significant asymmetry in the conformational changes leading to the transition from the c- to the m-state,” with H6–H1–H2 moving more than H3–H4–H5 (Pasquadibisceglie et al., 2023-02; https://doi.org/10.3390/ijms24043946) (pasquadibisceglie2023insilicoanalysis pages 1-2, pasquadibisceglie2023insilicoanalysis pages 4-7). The same work used MD/docking to analyze pathogenic variants and proposed mechanisms by which Asp231His (matrix salt‑bridge network disruption) and Ala281Val (helix packing/conformational transition impairment) could destabilize transport function (pasquadibisceglie2023insilicoanalysis pages 18-19, pasquadibisceglie2023insilicoanalysis pages 2-4, pasquadibisceglie2023insilicoanalysis pages 4-7).

3.3 Chemical entities (metabolites/drugs; CHEBI names provided) Disease‑relevant metabolites/biomarkers (plasma/DBS): - Free carnitine (C0) (decreased) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, elgharbawy2018inbornerrorsof pages 4-6) - Long‑chain acylcarnitines: C16 (palmitoylcarnitine), C18, C18:1 (oleoylcarnitine) (elevated) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, elgharbawy2018inbornerrorsof pages 4-6) - Dicarboxylic acids in urine (reflecting alternative oxidation routes) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, kheirandish2024theroleof pages 8-8)

Therapeutically relevant chemicals: - Medium‑chain triglycerides (MCT oil; octanoate/decanoate mixtures) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, penaquintana2024nutritionalmanagementof pages 5-6) - Triheptanoin (C7 triglyceride; UX007/Dojolvi): anaplerotic odd‑chain triglyceride used in LC‑FAOD, including CACTD (mahapatra2018triheptanoinarescue pages 1-2, wanders2020mitochondrialfattyacid pages 12-13, NCT03773770 chunk 1).

3.4 Cell types and anatomical locations (CL/UBERON names provided) Primary vulnerable tissues/cell types (consistent across clinical/pathology reports): - Cardiomyocytes / heart (arrhythmia, cardiomyopathy; lipid accumulation) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2) - Skeletal muscle fibers / skeletal muscle (weakness, rhabdomyolysis; lipid accumulation) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, elgharbawy2018inbornerrorsof pages 4-6) - Hepatocytes / liver (microvesicular steatosis, hepatomegaly, dysfunction) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency media 218ed3a6) - Renal proximal tubular epithelial cells / kidney cortex (fatty change; energy failure) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2) - Central nervous system/brain involvement (encephalopathy, seizures) (kheirandish2024theroleof pages 7-8, elgharbawy2018inbornerrorsof pages 4-6)

4) Biological processes disrupted (GO-style process names) GO‑relevant disrupted processes (process names; suitable for GO annotation workflows): - Long‑chain fatty acid metabolic process / mitochondrial fatty acid β‑oxidation (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, elgharbawy2018inbornerrorsof pages 4-6) - Acylcarnitine transmembrane transport / mitochondrial inner membrane transport (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5, pasquadibisceglie2023insilicoanalysis pages 1-2) - Ketone body metabolic process (impaired ketogenesis; hypoketosis) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2) - Response to fasting / energy homeostasis during catabolic stress (clinical decompensation with fasting/illness) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2) - Lipid storage and triglyceride metabolic process (microvesicular steatosis across organs) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency media 218ed3a6)

5) Cellular components (GO-style component names) Key cellular components implicated: - Mitochondrial inner membrane (site of SLC25A20/CACT) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5, pasquadibisceglie2023insilicoanalysis pages 1-2) - Mitochondrial matrix (destination for acyl groups for β‑oxidation) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5) - Cytosol (site of fatty‑acid mobilization and carnitine ester formation prior to import) (mahapatra2018triheptanoinarescue pages 1-2) - Lipid droplets / cytoplasmic lipid inclusions (histologic correlate of steatosis) (thunga2024carnitineacylcarnitinetranslocasedeficiency media 218ed3a6)

6) Disease progression (sequence of events and phases)

6.1 Trigger-to-crisis sequence A commonly described sequence is: catabolic trigger (birth transition, fasting, infection/illness) → increased reliance on LCFA oxidation → inability to import/oxidize long‑chain acylcarnitines → hypoketotic hypoglycemia (may be refractory), hyperammonemia, and rapid multi‑organ dysfunction (cardiac, hepatic, renal, muscle) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2).

6.2 Pathological tissue evolution Multi‑organ lipid accumulation is a key cellular pathology. In a 2024 autopsy case, diffuse microvesicular steatosis was reported in hepatocytes, cardiac myocytes, renal proximal tubular epithelium, skeletal muscle, and pancreatic acini (Thunga et al., 2024-04; https://doi.org/10.4322/acr.2024.483) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2). Representative liver histology showing microvesicular fat is shown in Thunga et al. 2024 (Figure 3) (thunga2024carnitineacylcarnitinetranslocasedeficiency media 218ed3a6).

7) Phenotypic manifestations (clinical phenotypes and mechanistic links)

7.1 Key phenotypes (HPO-style names) - Hypoketotic hypoglycemia / non‑ketotic hypoglycemia: mechanistically from failure of fatty‑acid–derived ketone production and ATP generation (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2). - Hyperammonemia: frequently observed during crises; in one autopsy case ammonia rose from 249 μmol/L to 433.5 μmol/L (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2). - Cardiomyopathy and cardiac arrhythmia: due to heart’s reliance on LCFA oxidation and toxicity/energy deficit; often a determinant of mortality (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, elgharbawy2018inbornerrorsof pages 4-6). - Hepatomegaly / hepatic dysfunction and microvesicular steatosis: consistent with impaired mitochondrial fat handling and secondary lipid accumulation (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency media 218ed3a6). - Rhabdomyolysis / myopathy (in surviving/older presentations): impaired muscle energy metabolism and toxic metabolite accumulation (elgharbawy2018inbornerrorsof pages 4-6). - Encephalopathy / seizures / coma: secondary to systemic metabolic decompensation and energy failure (kheirandish2024theroleof pages 7-8, elgharbawy2018inbornerrorsof pages 4-6).

7.2 Mortality and epidemiologic notes A 2015 literature review/series reported that CACTD typically presents neonatally (~82%) or in infancy (~18%) and has high mortality (~65%), often within the first year, frequently related to cardiomyopathy or sudden death (Vitoria et al., 2015-01; https://doi.org/10.1007/8904_2014_382) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2). A 2024 autopsy case report similarly cites first‑year mortality “up to 65%” and notes FAOD as a contributor to sudden unexpected death in infancy (SUDI) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8).

8) Recent developments (prioritizing 2023–2024)

8.1 Newborn screening: improved marker strategy (2023) A 2023 study addressed misclassification risk when relying only on single long‑chain acylcarnitines (C12–C18 series) in tandem MS/MS newborn screening and proposed ratio indices to improve discrimination (Shi et al., 2023-05; https://doi.org/10.21037/tp-22-468) (shi2023increasedacylcarnitineratio pages 1-2, shi2023increasedacylcarnitineratio pages 8-10).

Key ratio markers highlighted as elevated in all 15 genetically confirmed cases included: - (C16 + C18:1)/C2, C16/C2, C16:1/C3, and C16:1‑OH/C3 (shi2023increasedacylcarnitineratio pages 1-2, shi2023increasedacylcarnitineratio pages 2-3).

Performance/statistics from their validation dataset: - In 28,261 screened newborns, ratio false‑positive rates (except (C16 + C18)/C0) were lower than single acylcarnitine indices: 0.02–0.08% vs 0.16–0.88% (shi2023increasedacylcarnitineratio pages 1-2, shi2023increasedacylcarnitineratio pages 8-10). - Example single‑marker false‑positive rates: C16 0.46% and C18 0.55% (shi2023increasedacylcarnitineratio pages 8-10).

Genotype note relevant to screening interpretation: - A recurrent splice variant c.199‑10T>G in SLC25A20 was common in this cohort (14/15 patients homozygous) and associated with severe early onset; the authors discuss that carriers may have normal long‑chain acylcarnitine concentrations (shi2023increasedacylcarnitineratio pages 8-10, shi2023increasedacylcarnitineratio pages 2-3).

8.2 SLC25A20 mechanistic biology: structure–function (2023) Pasquadibisceglie et al. (2023) used AlphaFold‑based modeling, MD, and docking to refine understanding of SLC25A20 substrate recognition and conformational gating, supporting an alternating‑access model with asymmetric helix motion and multi‑step substrate recognition (pasquadibisceglie2023insilicoanalysis pages 1-2, pasquadibisceglie2023insilicoanalysis pages 4-7). This provides a contemporary mechanistic framework for interpreting pathogenic variants, including Asp231His and Ala281Val (pasquadibisceglie2023insilicoanalysis pages 18-19, pasquadibisceglie2023insilicoanalysis pages 2-4).

8.3 Nutritional management updates (2024) A 2024 Nutrients review on FAOD dietary management (including long‑chain disorders such as CACTD) emphasizes: - Avoidance of fasting (with strategies such as nocturnal feeding) (penaquintana2024nutritionalmanagementof pages 5-6). - Long‑chain triglyceride restriction to ~10% of total energy to normalize plasma acylcarnitines while avoiding essential fatty‑acid deficiency (penaquintana2024nutritionalmanagementof pages 5-6). - Essential fatty‑acid intake targets (linoleic 3–4%; linolenic 0.5–1% of total calories) and MCT supplementation 10–25% of total energy (minimum effective ~10%) (Peña‑Quintana & Correcher‑Medina, 2024-08; https://doi.org/10.3390/nu16162707) (penaquintana2024nutritionalmanagementof pages 5-6).

8.4 Triheptanoin: real‑world effectiveness data (2024) A 2024 nationwide Italian retrospective cohort evaluated nine LC‑FAOD patients switching from MCT oil to triheptanoin (Porta et al., 2024-10; https://doi.org/10.1186/s13052-024-01782-y) (porta2024triheptanoininpatients pages 2-4, porta2024triheptanoininpatients pages 1-2).

Quantitative outcomes after switching to triheptanoin: - Mean triheptanoin dose: 1.5 ± 0.9 g/kg/day, ~24 ± 9% of total daily calories, divided into 4 daily administrations (porta2024triheptanoininpatients pages 2-4). - Intercurrent catabolic episodes: 4.3 ± 5.3 (triheptanoin) vs 22.0 ± 22.2 (MCT), p=0.034 (porta2024triheptanoininpatients pages 2-4). - Hospitalizations for metabolic decompensation: 2.0 ± 2.5 (triheptanoin) vs 18.3 ± 17.7 (MCT), p=0.014 (porta2024triheptanoininpatients pages 2-4). - Annualized hospitalizations: 0.7 ± 0.8 vs 3.1 ± 3.0 per year, p=0.03; mean days per hospitalization: 3.6 ± 3.4 vs 10.5 ± 5.0, p=0.004 (porta2024triheptanoininpatients pages 2-4). - ICU admissions: 0 on triheptanoin vs 4 ICU admissions among 3 patients on MCT (porta2024triheptanoininpatients pages 2-4). - Adverse effects were mainly gastrointestinal (epigastric pain, diarrhea), similar to MCT (porta2024triheptanoininpatients pages 1-2, porta2024triheptanoininpatients pages 4-6).

Note: This cohort was heterogeneous (primarily MTPD/CPT2D/VLCADD), but the paper describes triheptanoin’s availability/usage in LC‑FAOD broadly, including CACTD in its reported diagnostic spectrum (porta2024triheptanoininpatients pages 1-2).

9) Current applications and real‑world implementations

9.1 Newborn screening (MS/MS) and confirmatory testing CACTD is screened via acylcarnitine profiling in dried blood spots using tandem mass spectrometry (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, shi2023increasedacylcarnitineratio pages 1-2). Because CACTD acylcarnitine profiles can overlap with CPT2 deficiency, confirmatory testing commonly requires SLC25A20 sequencing and/or functional assays (elgharbawy2018inbornerrorsof pages 4-6, vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2).

Practical screening enhancement (real‑world algorithm update): Shi et al. (2023) supports adding ratio indices such as (C16 + C18:1)/C2, C16/C2, C16:1/C3, and C16:1‑OH/C3 to improve sensitivity and reduce false positives relative to single long‑chain acylcarnitines (shi2023increasedacylcarnitineratio pages 1-2, shi2023increasedacylcarnitineratio pages 8-10).

9.2 Acute crisis management (implementation themes) Clinical reports/reviews emphasize emergency reversal of catabolism: intravenous glucose, avoidance of fasting, and dietary strategies that reduce reliance on LCFA oxidation (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2). These strategies are consistent with FAOD diet guidance (LCT restriction, carbohydrate support, MCT supplementation) in recent nutrition guidance (penaquintana2024nutritionalmanagementof pages 5-6).

9.3 Triheptanoin as an anaplerotic energy therapy Mechanistic rationale: triheptanoin is metabolized to heptanoate, producing acetyl‑CoA and propionyl‑CoA; propionyl‑CoA replenishes TCA intermediates (anaplerosis) via succinyl‑CoA, potentially mitigating energy deficiency in LC‑FAOD (wanders2020mitochondrialfattyacid pages 12-13).

CACTD‑specific clinical implementation evidence: a 2018 case report of an infant with genetically confirmed CACTD in cardiogenic shock described rapid recovery of cardiac function after triheptanoin initiation: ejection fraction increased from 24.9 to 73.7% within 72 hours and vasoactives were weaned, followed by discharge; the child remained on triheptanoin long‑term though later died at age 3 during an intercurrent illness (Mahapatra et al., 2018-01; https://doi.org/10.1007/8904_2017_36) (mahapatra2018triheptanoinarescue pages 2-4, mahapatra2018triheptanoinarescue pages 1-2).

Expanded access implementation: ClinicalTrials.gov lists an Expanded Access program for triheptanoin (UX007/Dojolvi) for LC‑FAOD explicitly including CACT/SLC25A20 deficiency (NCT03773770; https://clinicaltrials.gov/study/NCT03773770) (NCT03773770 chunk 1).

10) Expert opinion and interpretive analysis (authoritative synthesis)

10.1 Prognostic determinants A major interpretive theme from the CACTD literature is that outcomes correlate strongly with cardiac involvement and residual LCFA oxidation capacity rather than with a single enzyme activity metric alone (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2). This is consistent with high myocardial reliance on LCFA oxidation and the frequent lethal arrhythmia/cardiomyopathy phenotype (elgharbawy2018inbornerrorsof pages 4-6, vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2).

10.2 Screening limitations and the “early‑onset before sample” problem Shi et al. (2023) emphasize that CACTD often presents before routine newborn screening collection (e.g., routine 72-hour DBS timing in some systems), creating a structural limitation for prevention of the earliest crises; thus, improving discrimination (ratios) reduces false positives, but timing constraints still matter for clinical impact (shi2023increasedacylcarnitineratio pages 8-10).

10.3 Treatment landscape: diet + anaplerosis Recent nutritional guidance frames dietary management as a metabolic “catabolism avoidance” strategy (high carbohydrate availability, LCT restriction, essential fatty acids, and MCT/triheptanoin as alternative fuels) (penaquintana2024nutritionalmanagementof pages 5-6). Triheptanoin is increasingly treated as a pragmatic escalation for patients with ongoing episodes despite standard therapy, supported by real‑world data showing reduction in hospitalizations and catabolic episodes (porta2024triheptanoininpatients pages 2-4, porta2024triheptanoininpatients pages 6-9).

11) Evidence items (knowledge‑base ready; with identifiers and sources)

11.1 Gene/protein annotations - SLC25A20 (CACT/CAC): causal; mitochondrial inner membrane acylcarnitine/carnitine exchanger essential for LCFA β‑oxidation (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5). - Mechanistic/structure evidence: alternating access; asymmetric helix motion; pathogenic variant interpretation (Asp231His, Ala281Val) via MD/docking (pasquadibisceglie2023insilicoanalysis pages 1-2, pasquadibisceglie2023insilicoanalysis pages 18-19).

11.2 Ontology-style mappings (names) - GO biological processes (names): mitochondrial long‑chain fatty acid β‑oxidation; acylcarnitine transmembrane transport; ketone body metabolic process; response to fasting; lipid storage (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8). - GO cellular components (names): mitochondrial inner membrane; mitochondrial matrix; lipid droplet (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5, thunga2024carnitineacylcarnitinetranslocasedeficiency media 218ed3a6). - HPO phenotype terms (names): hypoketotic hypoglycemia; hyperammonemia; cardiomyopathy; cardiac arrhythmia; hepatomegaly; microvesicular steatosis; rhabdomyolysis; seizures/encephalopathy; sudden death (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, elgharbawy2018inbornerrorsof pages 4-6, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2). - CL cell types (names): hepatocyte; cardiomyocyte; skeletal muscle fiber; renal proximal tubule epithelial cell; neurons/astrocytes (clinical CNS involvement) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2, kheirandish2024theroleof pages 7-8). - UBERON anatomy (names): liver; heart; skeletal muscle; kidney (renal cortex/proximal tubule); pancreas (exocrine) (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8, thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2). - CHEBI chemical entities (names): carnitine; palmitoylcarnitine (C16); oleoylcarnitine (C18:1); medium‑chain triglycerides; triheptanoin; glucose (acute treatment) (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, mahapatra2018triheptanoinarescue pages 2-4, porta2024triheptanoininpatients pages 2-4).

11.3 Visual evidence - SLC25A20/CACT function in the carnitine shuttle (schematic): Thunga et al. 2024 Figure 4 (thunga2024carnitineacylcarnitinetranslocasedeficiency media a9332e20). - Microvesicular steatosis in CACTD liver histology: Thunga et al. 2024 Figure 3 (thunga2024carnitineacylcarnitinetranslocasedeficiency media 218ed3a6).

12) Key URLs and publication dates (most relevant sources) - Thunga et al. “Carnitine‑acylcarnitine translocase deficiency: a case report with autopsy.” Autopsy & Case Reports. 2024‑04. https://doi.org/10.4322/acr.2024.483 (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8) - Shi et al. “Increased acylcarnitine ratio indices in newborn screening for CACT deficiency…” Translational Pediatrics. 2023‑05. https://doi.org/10.21037/tp-22-468 (shi2023increasedacylcarnitineratio pages 1-2) - Pasquadibisceglie et al. “In Silico Analysis… SLC25A20 Transporter.” Int J Mol Sci. 2023‑02. https://doi.org/10.3390/ijms24043946 (pasquadibisceglie2023insilicoanalysis pages 1-2) - Peña‑Quintana & Correcher‑Medina. “Nutritional Management of Patients with Fatty Acid Oxidation Disorders.” Nutrients. 2024‑08. https://doi.org/10.3390/nu16162707 (penaquintana2024nutritionalmanagementof pages 5-6) - Porta et al. “Triheptanoin in patients with LC‑FAOD: clinical experience in Italy.” Italian Journal of Pediatrics. 2024‑10. https://doi.org/10.1186/s13052-024-01782-y (porta2024triheptanoininpatients pages 2-4) - Mahapatra et al. “Triheptanoin: A Rescue Therapy for Cardiogenic Shock in CACT Deficiency.” JIMD Reports. 2018‑01. https://doi.org/10.1007/8904_2017_36 (mahapatra2018triheptanoinarescue pages 2-4) - ClinicalTrials.gov Expanded Access triheptanoin (Dojolvi/UX007) including CACTD: NCT03773770. https://clinicaltrials.gov/study/NCT03773770 (NCT03773770 chunk 1)

Limitations of this report - Several mechanistic statements in contemporary clinical reviews typically include PMID‑indexed primary citations; however, the retrieved evidence snippets available here did not consistently surface PMIDs in-text. Therefore, this report provides DOI/URL‑based citations and journal metadata for traceability, and uses extracted evidence only for all major claims (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2, shi2023increasedacylcarnitineratio pages 1-2, pasquadibisceglie2023insilicoanalysis pages 1-2).

References

  1. (vitoria2015carnitineacylcarnitinetranslocasedeficiency pages 1-2): Isidro Vitoria, Elena Martín-Hernández, Luis Peña-Quintana, María Bueno, Pilar Quijada-Fraile, Jaime Dalmau, Sofia Molina-Marrero, Belén Pérez, and Begoña Merinero. Carnitine-acylcarnitine translocase deficiency: experience with four cases in spain and review of the literature. JIMD reports, 20:11-20, Jan 2015. URL: https://doi.org/10.1007/8904_2014_382, doi:10.1007/8904_2014_382. This article has 52 citations and is from a peer-reviewed journal.

  2. (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 5-8): Chennakeshava Thunga, Suvradeep Mitra, Devi Dayal, and Sadhna Lal. Carnitine-acylcarnitine translocase deficiency: a case report with autopsy. Autopsy & Case Reports, 14:e2024483, Apr 2024. URL: https://doi.org/10.4322/acr.2024.483, doi:10.4322/acr.2024.483. This article has 2 citations.

  3. (elgharbawy2018inbornerrorsof pages 4-6): Areeg El-Gharbawy and Jerry Vockley. Inborn errors of metabolism with myopathy. Apr 2018. URL: https://doi.org/10.1016/j.pcl.2017.11.006, doi:10.1016/j.pcl.2017.11.006. This article has 119 citations and is from a peer-reviewed journal.

  4. (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 2-5): Chennakeshava Thunga, Suvradeep Mitra, Devi Dayal, and Sadhna Lal. Carnitine-acylcarnitine translocase deficiency: a case report with autopsy. Autopsy & Case Reports, 14:e2024483, Apr 2024. URL: https://doi.org/10.4322/acr.2024.483, doi:10.4322/acr.2024.483. This article has 2 citations.

  5. (thunga2024carnitineacylcarnitinetranslocasedeficiency media a9332e20): Chennakeshava Thunga, Suvradeep Mitra, Devi Dayal, and Sadhna Lal. Carnitine-acylcarnitine translocase deficiency: a case report with autopsy. Autopsy & Case Reports, 14:e2024483, Apr 2024. URL: https://doi.org/10.4322/acr.2024.483, doi:10.4322/acr.2024.483. This article has 2 citations.

  6. (thunga2024carnitineacylcarnitinetranslocasedeficiency pages 1-2): Chennakeshava Thunga, Suvradeep Mitra, Devi Dayal, and Sadhna Lal. Carnitine-acylcarnitine translocase deficiency: a case report with autopsy. Autopsy & Case Reports, 14:e2024483, Apr 2024. URL: https://doi.org/10.4322/acr.2024.483, doi:10.4322/acr.2024.483. This article has 2 citations.

  7. (kheirandish2024theroleof pages 8-8): Ali Kheirandish, Reza Shah Hosseini, Shirin Yaghoobpoor, Ashkan Bahrami, Alireza Aghajani, M. Fathi, Milad Alipour, Ameneh Zarebidoki, and Ashraf Mohamadkhani. The role of genetic defects in carnitine-associated hepatic encephalopathy: a review of literature. Gastroenterology and Hepatology From Bed to Bench, 17:357-378, 2024. URL: https://doi.org/10.22037/ghfbb.v17i4.2960, doi:10.22037/ghfbb.v17i4.2960. This article has 0 citations and is from a peer-reviewed journal.

  8. (pasquadibisceglie2023insilicoanalysis pages 1-2): Andrea Pasquadibisceglie, Virginia Quadrotta, and Fabio Polticelli. In silico analysis of the structural dynamics and substrate recognition determinants of the human mitochondrial carnitine/acylcarnitine slc25a20 transporter. International Journal of Molecular Sciences, Feb 2023. URL: https://doi.org/10.3390/ijms24043946, doi:10.3390/ijms24043946. This article has 12 citations.

  9. (thunga2024carnitineacylcarnitinetranslocasedeficiency media 218ed3a6): Chennakeshava Thunga, Suvradeep Mitra, Devi Dayal, and Sadhna Lal. Carnitine-acylcarnitine translocase deficiency: a case report with autopsy. Autopsy & Case Reports, 14:e2024483, Apr 2024. URL: https://doi.org/10.4322/acr.2024.483, doi:10.4322/acr.2024.483. This article has 2 citations.

  10. (pasquadibisceglie2023insilicoanalysis pages 4-7): Andrea Pasquadibisceglie, Virginia Quadrotta, and Fabio Polticelli. In silico analysis of the structural dynamics and substrate recognition determinants of the human mitochondrial carnitine/acylcarnitine slc25a20 transporter. International Journal of Molecular Sciences, Feb 2023. URL: https://doi.org/10.3390/ijms24043946, doi:10.3390/ijms24043946. This article has 12 citations.

  11. (pasquadibisceglie2023insilicoanalysis pages 18-19): Andrea Pasquadibisceglie, Virginia Quadrotta, and Fabio Polticelli. In silico analysis of the structural dynamics and substrate recognition determinants of the human mitochondrial carnitine/acylcarnitine slc25a20 transporter. International Journal of Molecular Sciences, Feb 2023. URL: https://doi.org/10.3390/ijms24043946, doi:10.3390/ijms24043946. This article has 12 citations.

  12. (pasquadibisceglie2023insilicoanalysis pages 2-4): Andrea Pasquadibisceglie, Virginia Quadrotta, and Fabio Polticelli. In silico analysis of the structural dynamics and substrate recognition determinants of the human mitochondrial carnitine/acylcarnitine slc25a20 transporter. International Journal of Molecular Sciences, Feb 2023. URL: https://doi.org/10.3390/ijms24043946, doi:10.3390/ijms24043946. This article has 12 citations.

  13. (penaquintana2024nutritionalmanagementof pages 5-6): Luis Peña-Quintana and Patricia Correcher-Medina. Nutritional management of patients with fatty acid oxidation disorders. Nutrients, 16:2707, Aug 2024. URL: https://doi.org/10.3390/nu16162707, doi:10.3390/nu16162707. This article has 7 citations.

  14. (mahapatra2018triheptanoinarescue pages 1-2): Sidharth Mahapatra, Amitha Ananth, Nancy Baugh, Mihaela Damian, and Gregory M. Enns. Triheptanoin: a rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency. JIMD reports, 39:19-23, Jan 2018. URL: https://doi.org/10.1007/8904_2017_36, doi:10.1007/8904_2017_36. This article has 24 citations and is from a peer-reviewed journal.

  15. (wanders2020mitochondrialfattyacid pages 12-13): Ronald J.A. Wanders, Gepke Visser, Sacha Ferdinandusse, Frédéric M. Vaz, and Riekelt H. Houtkooper. Mitochondrial fatty acid oxidation disorders: laboratory diagnosis, pathogenesis, and the complicated route to treatment. Journal of Lipid and Atherosclerosis, 9:313-333, Jul 2020. URL: https://doi.org/10.12997/jla.2020.9.3.313, doi:10.12997/jla.2020.9.3.313. This article has 81 citations.

  16. (NCT03773770 chunk 1): Expanded Access to Triheptanoin. Ultragenyx Pharmaceutical Inc. ClinicalTrials.gov Identifier: NCT03773770

  17. (kheirandish2024theroleof pages 7-8): Ali Kheirandish, Reza Shah Hosseini, Shirin Yaghoobpoor, Ashkan Bahrami, Alireza Aghajani, M. Fathi, Milad Alipour, Ameneh Zarebidoki, and Ashraf Mohamadkhani. The role of genetic defects in carnitine-associated hepatic encephalopathy: a review of literature. Gastroenterology and Hepatology From Bed to Bench, 17:357-378, 2024. URL: https://doi.org/10.22037/ghfbb.v17i4.2960, doi:10.22037/ghfbb.v17i4.2960. This article has 0 citations and is from a peer-reviewed journal.

  18. (shi2023increasedacylcarnitineratio pages 1-2): Congcong Shi, Zhenzhen Ao, Bingqing Liu, Xin Xiao, Xia Gu, Qiuping Yang, Hu Hao, Yao Cai, and Sitao Li. Increased acylcarnitine ratio indices in newborn screening for carnitine-acylcarnitine translocase deficiency shows increased sensitivity and reduced false-positivity. Translational Pediatrics, 12:871-881, May 2023. URL: https://doi.org/10.21037/tp-22-468, doi:10.21037/tp-22-468. This article has 9 citations and is from a peer-reviewed journal.

  19. (shi2023increasedacylcarnitineratio pages 8-10): Congcong Shi, Zhenzhen Ao, Bingqing Liu, Xin Xiao, Xia Gu, Qiuping Yang, Hu Hao, Yao Cai, and Sitao Li. Increased acylcarnitine ratio indices in newborn screening for carnitine-acylcarnitine translocase deficiency shows increased sensitivity and reduced false-positivity. Translational Pediatrics, 12:871-881, May 2023. URL: https://doi.org/10.21037/tp-22-468, doi:10.21037/tp-22-468. This article has 9 citations and is from a peer-reviewed journal.

  20. (shi2023increasedacylcarnitineratio pages 2-3): Congcong Shi, Zhenzhen Ao, Bingqing Liu, Xin Xiao, Xia Gu, Qiuping Yang, Hu Hao, Yao Cai, and Sitao Li. Increased acylcarnitine ratio indices in newborn screening for carnitine-acylcarnitine translocase deficiency shows increased sensitivity and reduced false-positivity. Translational Pediatrics, 12:871-881, May 2023. URL: https://doi.org/10.21037/tp-22-468, doi:10.21037/tp-22-468. This article has 9 citations and is from a peer-reviewed journal.

  21. (porta2024triheptanoininpatients pages 2-4): Francesco Porta, Arianna Maiorana, Vincenza Gragnaniello, Elena Procopio, Serena Gasperini, Roberta Taurisano, Marco Spada, Carlo Dionisi-Vici, and Alberto Burlina. Triheptanoin in patients with long-chain fatty acid oxidation disorders: clinical experience in italy. Italian Journal of Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s13052-024-01782-y, doi:10.1186/s13052-024-01782-y. This article has 10 citations and is from a peer-reviewed journal.

  22. (porta2024triheptanoininpatients pages 1-2): Francesco Porta, Arianna Maiorana, Vincenza Gragnaniello, Elena Procopio, Serena Gasperini, Roberta Taurisano, Marco Spada, Carlo Dionisi-Vici, and Alberto Burlina. Triheptanoin in patients with long-chain fatty acid oxidation disorders: clinical experience in italy. Italian Journal of Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s13052-024-01782-y, doi:10.1186/s13052-024-01782-y. This article has 10 citations and is from a peer-reviewed journal.

  23. (porta2024triheptanoininpatients pages 4-6): Francesco Porta, Arianna Maiorana, Vincenza Gragnaniello, Elena Procopio, Serena Gasperini, Roberta Taurisano, Marco Spada, Carlo Dionisi-Vici, and Alberto Burlina. Triheptanoin in patients with long-chain fatty acid oxidation disorders: clinical experience in italy. Italian Journal of Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s13052-024-01782-y, doi:10.1186/s13052-024-01782-y. This article has 10 citations and is from a peer-reviewed journal.

  24. (mahapatra2018triheptanoinarescue pages 2-4): Sidharth Mahapatra, Amitha Ananth, Nancy Baugh, Mihaela Damian, and Gregory M. Enns. Triheptanoin: a rescue therapy for cardiogenic shock in carnitine-acylcarnitine translocase deficiency. JIMD reports, 39:19-23, Jan 2018. URL: https://doi.org/10.1007/8904_2017_36, doi:10.1007/8904_2017_36. This article has 24 citations and is from a peer-reviewed journal.

  25. (porta2024triheptanoininpatients pages 6-9): Francesco Porta, Arianna Maiorana, Vincenza Gragnaniello, Elena Procopio, Serena Gasperini, Roberta Taurisano, Marco Spada, Carlo Dionisi-Vici, and Alberto Burlina. Triheptanoin in patients with long-chain fatty acid oxidation disorders: clinical experience in italy. Italian Journal of Pediatrics, Oct 2024. URL: https://doi.org/10.1186/s13052-024-01782-y, doi:10.1186/s13052-024-01782-y. This article has 10 citations and is from a peer-reviewed journal.